Name: investigating the protective effects of platycodin d on non-alcoholic fatty liver disease in a palmitic acid-induced in vitro model
Uploaded: 2022-12-02T15:00:00
Description: Watch this Scientific Journal Video about Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model at JoVE.com

This work is supported by grants from the Chongqing Science and Technology Commission (cstc2020jxjl-jbky10002, jbky20200026, cstc2021jscx-dxwtBX0013, and jbky20210029) and the China Postdoctoral Science Foundation (No. 2021MD703919).

AML-12 cells (a normal mouse hepatocyte cell line) are used for the cell-based studies. The cells are obtained from a commercial source (see Table of Materials).
1. Pretreatment of the AML-12 cells to model NAFLD in vitro
<ol>
	<li>Maintain the cells in normal cell culture media (DMEM plus Ham&#39;s F12 [1:1] containing 0.005 mg/mL insulin, 5 ng/mL selenium, 0.005 mg/mL transferrin, 40 ng/mL dexamethasone, and 10% fetal bovine serum [FBS], see <str...

Studies have highlighted the fact that NAFLD is a clinicopathological syndrome, ranging from fatty liver to NASH, that can progress to cirrhosis and liver cancer51. A high-fat diet and an inactive lifestyle are typical risk factors for NAFLD. Both non-drug therapies and drug therapies for NAFLD treatment have been researched51,52,53. However, the pathogenesis of NAFLD has not been fully elucidated. The me...

Platycodon grandiflorus (PG), which is the dried root of Platycodon grandiflorus (Jacq.) A.DC., is used in traditional Chinese medicine (TCM). It is mainly produced in the northeast, north, east, central, and southwest regions of China1. The PG components include triterpenoid saponins, polysaccharides, flavonoids, polyphenols, polyethylene glycols, volatile oils, and minerals2. PG has a long history of being used as a food and a herbal medicine in Asia. Traditionally, this herb was used to make medicine against lung diseases. Modern pharmacology also provides evidence of the efficacy of PG for treating other diseases. Studies have shown that PG has a therapeutic effect on a variety of drug-induced liver injury models. The dietary supplementation of PG or platycodin extracts can ameliorate high-fat diet-induced obesity and its related metabolic diseases3,4,5. Polysaccharides from PG can be used for the treatment of acute liver injury caused by LPS/D-GalN in mice6. Moreover, saponins from the roots of PG ameliorate high-fat diet-induced non-alcoholic steatohepatitis (NASH)7. Furthermore, platycodin D (PD), one of the most important therapeutic components of PG, can enhance low-density lipoprotein receptor expression and low-density lipoprotein uptake in human hepatocellular carcinoma (HepG2) cells8. Furthermore, PD can also induce apoptosis and inhibit adhesion, migration, and invasion in HepG2 cells9,10. Thus, in this study, mouse hepatoma AML-12 cells are used for in vitro model construction and to further study the pharmacological effects and underlying mechanisms of PD in this model.
The term non-alcoholic fatty liver disease (NAFLD) refers to a group of liver diseases that includes simple steatosis, NASH, cirrhosis, and hepatocellular carcinoma11. Although the pathogenesis of NAFLD is incompletely understood, from the classic &#34;two-hit&#34; theory to the current &#34;multiple-hit&#34; theory, insulin resistance is considered to be central in the pathogenesis of NAFLD12,13,14. Studies have demonstrated that insulin resistance in hepatocytes could lead to increased free fatty acids, which form triglycerides that are deposited in the liver and cause the liver to become fatty15,16. The accumulation of fat can lead to lipotoxicity, oxidative stress-induced mitochondrial dysfunction, endoplasmic reticulum stress, and inflammatory cytokine release, resulting in the pathogenesis and progression of NAFLD17,18. In addition, autophagy also plays a role in the pathogenesis of NAFLD, as it is involved in regulating cellular insulin sensitivity, cellular lipid metabolism, hepatocyte injury, and innate immunity19,20,21.
A variety of animal models and cellular models have been established to provide a basis for exploring the pathogenesis and potential therapeutic targets of NAFLD22,23. However, single animal models cannot fully mimic all the pathological processes of NAFLD24. Individual differences between animals lead to different pathological features. Using liver cell lines or primary hepatocytes in in vitro studies of NAFLD ensures maximum consistency in the experimental conditions. Hepatic lipid metabolism dysregulation can lead to higher levels of hepatocyte lipid droplet accumulation in NAFLD25. Free fatty acids such as oleic acid and palm oil have been used in the in vitro model to mimic NAFLD caused by a high-fat diet26,27. The human hepatoblastoma cell line HepG2 is often used in the construction of NAFLD models in vitro, but, as a tumor cell line, the metabolism of HepG2 cells is significantly different from that of liver cells under normal physiological conditions28. Therefore, using primary hepatocytes or mouse primary hepatocytes to construct the in vitro NAFLD model for drug screening is more advantageous than using tumor cell lines. Comparing the synergistic examination of drug effects and therapeutic targets in both animal models and in vitro hepatocyte models, it seems that using mouse hepatocytes to construct the in vitro NAFLD model has better application potential.
Free fatty acids entering the liver are oxidized to produce energy or stored as triglycerides. Significantly, free fatty acids have a certain lipotoxicity and may induce cellular dysfunction and apoptosis12. Palmitic acid (PA) is the most abundant saturated fatty acid in human plasma29. When cells in non-adipose tissue are exposed to high concentrations of PA for a long time, this stimulates the production of reactive oxygen species (ROS) and causes oxidative stress, lipid accumulation, and even apoptosis30. Therefore, many researchers use PA as an inducer to stimulate liver cells to produce ROS and, thus, construct the in vitro fatty liver disease model and evaluate the protective effects of certain active substances on cells31,32,33,34. This study introduces a protocol for investigating the protective effects of PD on a cell model of NAFLD induced by PA.

<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>5% BSA Blocking Buffer</td>
			<td>Solarbio, Beijing, China</td>
			<td>SW3015</td>
			<td></td>
		</tr>
		<tr>
			<td>AML12 (alpha mouse liver 12) cell line</td>
			<td>Procell Life Science&#38;Technology Co., Ltd, China</td>
			<td>AML12</td>
			<td></td>
		</tr>
		<tr>
			<td>Beyo ECL&#160;Plus</td>
			<td>Beyotime, Shanghai, China</td>
			<td>P0018S</td>
			<td></td>
		</tr>
		<tr>
			<td>Bio-safety cabinet</td>
			<td>Esco Micro Pte Ltd, Singapore</td>
			<td>AC2-5S1 A2&#160;</td>
			<td></td>
		</tr>
		<tr>
			<td>cellSens</td>
			<td>Olympus, Tokyo, Japan</td>
			<td>1.8</td>
			<td></td>
		</tr>
		<tr>
			<td>Culture CO2 Incubator</td>
			<td>Esco Micro Pte Ltd, Singapore</td>
			<td>CCL-170B-8</td>
			<td></td>
		</tr>
		<tr>
			<td>Dexamethasone</td>
			<td>Beyotime, Shanghai, China</td>
			<td>ST125</td>
			<td></td>
		</tr>
		<tr>
			<td>Dimethyl sulfoxide</td>
			<td>Solarbio, Beijing, China</td>
			<td>D8371</td>
			<td></td>
		</tr>
		<tr>
			<td>DMEM/F12</td>
			<td>Hyclone,&#160;Logan,&#160;UT,&#160;USA</td>
			<td>SH30023.01</td>
			<td></td>
		</tr>
		<tr>
			<td>Foetal Bovine Serum</td>
			<td>Hyclone, Tauranga, New Zealand</td>
			<td>SH30406.05</td>
			<td></td>
		</tr>
		<tr>
			<td>Graphpad software</td>
			<td>GraphPad Software Inc., San Diego, CA, USA</td>
			<td>8.0</td>
			<td></td>
		</tr>
		<tr>
			<td>HRP Goat Anti-Mouse IgG (H+L)</td>
			<td>ABclonal, Wuhan, China</td>
			<td>AS003</td>
			<td></td>
		</tr>
		<tr>
			<td>Hydrophobic PVDF Transfer Membrane</td>
			<td>Merck, Darmstadt, Germany</td>
			<td>IPFL00010</td>
			<td></td>
		</tr>
		<tr>
			<td>Insulin, Transferrin, Selenium Solution, 100&#215;</td>
			<td>Beyotime, Shanghai, China</td>
			<td>C0341</td>
			<td></td>
		</tr>
		<tr>
			<td>MAP LC3&#946; Antibody</td>
			<td>Santa Cruz Biotechnology (Shanghai) Co., Ltd</td>
			<td>SC-376404</td>
			<td></td>
		</tr>
		<tr>
			<td>Mitochondrial Membrane Potential Assay Kit with JC-1</td>
			<td>Solarbio, Beijing, China</td>
			<td>M8650</td>
			<td></td>
		</tr>
		<tr>
			<td>Olympus Inverted Microscope IX53</td>
			<td>Olympus, Tokyo, Japan</td>
			<td>IX53</td>
			<td></td>
		</tr>
		<tr>
			<td>Palmitic Acid</td>
			<td>Sigma, Germany</td>
			<td>P0500</td>
			<td></td>
		</tr>
		<tr>
			<td>Penicillin-Streptomycin Solution (100x)</td>
			<td>Hyclone,&#160;Logan,&#160;UT,&#160;USA</td>
			<td>SV30010</td>
			<td></td>
		</tr>
		<tr>
			<td>Phenylmethanesulfonyl&#160;fluoride</td>
			<td>Beyotime, Shanghai, China</td>
			<td>ST506</td>
			<td></td>
		</tr>
		<tr>
			<td>Phosphate Buffered Solution</td>
			<td>Hyclone,&#160;Logan,&#160;UT,&#160;USA</td>
			<td>BL302A</td>
			<td></td>
		</tr>
		<tr>
			<td>Platycodin D</td>
			<td>Chengdu Must Bio-Technology Co., Ltd, China</td>
			<td>CSA: 58479-68-8</td>
			<td></td>
		</tr>
		<tr>
			<td>Protease inhibitor cocktail for general use, 100x</td>
			<td>Beyotime, Shanghai, China</td>
			<td>P1005</td>
			<td></td>
		</tr>
		<tr>
			<td>Protein Marker</td>
			<td>Solarbio, Beijing, China</td>
			<td>PR1910</td>
			<td></td>
		</tr>
		<tr>
			<td>Reactive Oxygen Species Assay Kit</td>
			<td>Solarbio, Beijing, China</td>
			<td>CA1410</td>
			<td></td>
		</tr>
		<tr>
			<td>RIPA&#160;Lysis&#160;Buffer</td>
			<td>Beyotime, Shanghai, China</td>
			<td>P0013E</td>
			<td></td>
		</tr>
		<tr>
			<td>SDS-PAGE Gel Quick Preparation Kit</td>
			<td>Beyotime, Shanghai, China</td>
			<td>P0012AC</td>
			<td></td>
		</tr>
		<tr>
			<td>SDS-PAGE Sample Loading Buffer, 5x</td>
			<td>Beyotime, Shanghai, China</td>
			<td>P0015</td>
			<td></td>
		</tr>
		<tr>
			<td>Sigma Centrifuge</td>
			<td>Sigma, Germany</td>
			<td>3K15</td>
			<td></td>
		</tr>
		<tr>
			<td>SQSTM1/p62 Antibody</td>
			<td>Santa Cruz Biotechnology (Shanghai) Co., Ltd</td>
			<td>SC-28359</td>
			<td></td>
		</tr>
		<tr>
			<td>Tecan Infinite 200 PRO&#160;&#160;</td>
			<td>Tecan Austria GmbH, Austria</td>
			<td>1510002987</td>
			<td></td>
		</tr>
		<tr>
			<td>WB Transfer Buffer,10x</td>
			<td>Solarbio, Beijing, China</td>
			<td>D1060</td>
			<td></td>
		</tr>
		<tr>
			<td>&#946;-Actin Mouse mAb</td>
			<td>ABclonal, Wuhan, China</td>
			<td>AC004</td>
			<td></td>
		</tr>
	</tbody>
</table>

investigating the protective effects of platycodin d on non-alcoholic fatty liver disease in a palmitic acid-induced in vitro model

The occurrence of non-alcoholic fatty liver disease (NAFLD) has been increasing at an alarming rate worldwide. Platycodon grandiflorum is widely used as a traditional ethnomedicine for the treatment of various diseases and is a typical functional food that can be incorporated into the everyday diet. Studies have suggested that platycodin D (PD), one of the main active ingredients in Platycodon grandiflorum, has high bioavailability and significantly mitigates the progress of NAFLD, but the underlying mechanism of this is still unclear. This study aims to investigate the therapeutic effect of PD against NAFLD in vitro. AML-12 cells were pretreated with 300 &#181;M palmitic acid (PA) for 24 h to model NAFLD in vitro. Then, the cells were either treated with PD or received no PD treatment for 24 h. The levels of reactive oxygen species (ROS) were analyzed using 2&#8242;,7&#8242;-dichloro-dihydro-fluorescein diacetate (DCFH-DA) staining, and the mitochondrial membrane potential was determined by the JC-1 staining method. Moreover, the protein expression levels of LC3-II/LC3-I and p62/SQSTM1 in the cell lysates were analyzed by western blotting. PD was found to significantly decrease the ROS and mitochondrial membrane potential levels in the PA-treated group compared to the control group. Meanwhile, PD increased the LC3-II/LC3-I levels and decreased the p62/SQSTM1 levels in the PA-treated group compared to the control group. The results indicated that PD ameliorated NAFLD in vitro by reducing oxidative stress and stimulating autophagy. This in vitro model is a useful tool for studying the role of PD in NAFLD.

Intracellular ROS in the cells 
AML-12 cells were induced with 300 &#181;M PA for 24 h, and a NAFLD cell model was established. Subsequently, the cells were treated with PD for 24 h. The cells were labeled with a DCFH-DA fluorescent probe, and ROS production was observed under a fluorescence microscope. The results of the DCFH-DA staining of intracellular ROS in the cells are shown in Figure 1. The results showed that PD could significantly reduce the level of intracell...

Watch this Scientific Journal Video about Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model at JoVE.com

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model

This protocol investigates the protective effects of platycodin D on non-alcoholic fatty liver disease in a palmitic acid-induced in vitro model.

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model

The occurrence of non-alcoholic fatty liver disease (NAFLD) has been increasing at an alarming rate worldwide. Platycodon grandiflorum is widely used as a ...

Research

JoVE Journal

Medicine

Excitotoxic Stimulation of Brain Microslices as an In vitro Model of Stroke

Excitotoxic Stimulation of Brain Microslices as an In vitro Model of Stroke

Examining molecular mechanisms involved in neuropathological conditions, such as ischemic stroke, can be difficult when using whole animal systems. As ...

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

When proposing the use of a drug, drug combination, or drug delivery into a novel system, one must assess the pharmacokinetics of the drug in the study ...

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

The SOD1-G93A transgenic mouse is the most widely used animal model of amyotrophic lateral sclerosis (ALS). At ALS TDI we developed a phenotypic screening ...

The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat

Four to six week old, male Wistar rats were used to produce animal models of liver fibrosis. The process requires four weeks of administration of 10 mg/kg ...

In Vitro and In Vivo Detection of Mitophagy in Human Cells, C. Elegans, and Mice

In Vitro and In Vivo Detection of Mitophagy in Human Cells, C. Elegans, and Mice

Mitochondria are the powerhouses of cells and produce cellular energy in the form of ATP. Mitochondrial dysfunction contributes to biological aging and a ...

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Plasma coagulation as a form of electrocautery is used in liver surgery for decades to seal the large liver cut surface after major hepatectomy to prevent ...

Isometric Contractility Measurement of the Mouse Mesenteric Artery Using Wire Myography

The wire myograph technique is used to assess the contractility of vascular smooth muscles in response to depolarization, GPCR agonists/inhibitors and ...

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Clinical trials assessing therapies for the treatment of non-alcoholic steatohepatitis (NASH) involve a baseline and end of study liver biopsy, and ...

In Vitro Model of Coronary Angiogenesis

Here, we describe an in vitro culture assay to study coronary angiogenesis. Coronary vessels feed the heart muscle and are of clinical importance. Defects ...

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Understanding the mechanisms of liver injury, hepatic fibrosis, and cirrhosis that underlie chronic liver diseases (i.e., viral hepatitis, non-alcoholic ...